Topic: intellectual property
With the FBI and Genentech pushing for convictions in a trade secrets case, one defendant has chosen to cut a deal to escape possible jail time.
The Taiwanese firm will reimburse Genentech for legal and investigative fees but won't pay any damages. The ex-staffers involved may not be so lucky.
U.S. Rep. Elijah Cummings is leading an effort to determine if Gilead's largesse is tied to its efforts to protect Truvada's patents.
Credit Suisse analysts have uncovered a Novartis patent that they fear could be a threat to ozanimod, Celgene's phase 3 multiple sclerosis candidate.
A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.
Amgen and Sandoz faced off in oral arguments at the U.S. Supreme Court Wednesday in a case set to have a big impact on future biosim launches.
Biogen has settled its Tecfidera patent fight with Forward Pharma for a whopping $1.25 billion in upfront cash, plus potential royalties, sending Forward's shares skyward by 83% in premarket trading.
The National Intellectual Property Rights Policy will continue to see Trade-Related Aspects of Intellectual Property Rights as the bedrock for data exclusivity and patent rules.